CN115403566B - 3-取代吲哚-2-酮化合物及其制备方法和应用 - Google Patents
3-取代吲哚-2-酮化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN115403566B CN115403566B CN202211150957.5A CN202211150957A CN115403566B CN 115403566 B CN115403566 B CN 115403566B CN 202211150957 A CN202211150957 A CN 202211150957A CN 115403566 B CN115403566 B CN 115403566B
- Authority
- CN
- China
- Prior art keywords
- dimethyl
- pyrrol
- methylene
- indolone
- indol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- -1 3-substituted indol-2-one compound Chemical class 0.000 title claims description 238
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 14
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 14
- 201000005202 lung cancer Diseases 0.000 claims abstract description 14
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 14
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 12
- 239000011886 peripheral blood Substances 0.000 claims abstract description 12
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 6
- 208000032839 leukemia Diseases 0.000 claims abstract description 6
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 33
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 16
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- RDFZYUOHJBXMJA-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrrole-2-carbaldehyde Chemical compound CC1=CC(C)=C(C=O)N1 RDFZYUOHJBXMJA-UHFFFAOYSA-N 0.000 claims description 10
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims description 10
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 8
- 229940073608 benzyl chloride Drugs 0.000 claims description 8
- 150000005524 benzylchlorides Chemical class 0.000 claims description 8
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 229940125904 compound 1 Drugs 0.000 claims description 6
- 230000010261 cell growth Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 5
- 150000001263 acyl chlorides Chemical class 0.000 claims description 4
- 238000005882 aldol condensation reaction Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003966 growth inhibitor Substances 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 238000006396 nitration reaction Methods 0.000 claims description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000009036 growth inhibition Effects 0.000 abstract description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 8
- 125000001931 aliphatic group Chemical group 0.000 abstract description 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 5
- 239000001257 hydrogen Substances 0.000 abstract description 5
- 150000002431 hydrogen Chemical class 0.000 abstract description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 5
- 125000004076 pyridyl group Chemical group 0.000 abstract description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 5
- 229910052736 halogen Inorganic materials 0.000 abstract description 3
- 150000002367 halogens Chemical class 0.000 abstract description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 96
- 239000007787 solid Substances 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- 238000003756 stirring Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000012295 chemical reaction liquid Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000000967 suction filtration Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229950003647 semaxanib Drugs 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 244000061458 Solanum melongena Species 0.000 description 4
- 235000002597 Solanum melongena Nutrition 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical class OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- KGRJPLRFGLMQMV-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)methyl]indole-2,3-dione Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C2=CC=CC=C2C(=O)C1=O KGRJPLRFGLMQMV-UHFFFAOYSA-N 0.000 description 3
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 150000001559 benzoic acids Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000005625 indol-2-ones Chemical class 0.000 description 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229940081066 picolinic acid Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910014265 BrCl Inorganic materials 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种3‑取代吲哚‑2‑酮化合物及其制备方法和应用。本发明化合物具有如下式(I)、(II)或(III)所示结构：其中，R1、R2独立地选自氢、卤素、氰基、三氟甲基或甲氧基；R3选自苯基、取代苯基、吡啶基、脂肪烃基或取代脂肪烃基。该类化合物对人外周血T淋巴源性白血病细胞Jurkat、肺癌细胞A549和结肠癌细胞HCT116具有一定的生长抑制活性，可用于制备抗肿瘤药物。
Description
技术领域
本发明涉及有机化合物合成及医药应用领域，尤其涉及一种3-取代吲哚-2-酮化合物及其制备方法和应用。
背景技术
吲哚-2-酮是药物发现和药物开发中的一种特殊结构，由于取代的吲哚-2-酮与许多受体具有良好的亲和力，并且获批含有该分子骨架的药物数量众多，因此已被当作优先药物结构使用。(参见文献：Zhang L,Zheng Q,Yang Y,Zhou H,Gong X,Zhao S,FanC.Synthesis and in vivo SAR study of indolin-2-one-based multi-targetedinhibitors as potential anticancer agents.EUR J MED CHEM.2014,82,139-151.)。
血管几乎滋养着身体的每个器官，如果血管生长不正常，就会引诱诸如中风、心脏异变、溃疡和神经细胞发育障碍等许多血管性病变的触发，而异常的血管失衡或出芽还会引发癌症。现在越来越可以肯定的是，血管生成或新血管的再造在癌症的转变和转移进程中起着核心作用。(参见文献：Yang J,Yan J,Liu B.Targeting VEGF/VEGFR to modulateantitumor immunity.FRONT IMMUNOL.2018,9,978-986)。抗血管生成和促血管生成信号之间的微妙动态平衡调度着血管生成过程中的复杂驱动事件。血管内皮生长因子(VEGF)是已知的最特异、最关键的血管生成调度因子之一。(参见文献：Sitohy B,Nagy J A,Dvorak HF.Anti-VEGF/VEGFR therapy for cancer:Reassessing the target.CANCER RES.2012,72,1909-1914.)。司马沙尼(Semaxanib,SU5416，(Z)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)吲哚啉-2-酮)是基于吲哚-2-酮分子骨架设计并发现的一种有效的和选择性的VEGFR抑制剂，并对VEGFR-2具有很高的选择性。化合物AA-2(1-(3,4-二氯苄基)-1H-吲哚-2,3-二酮)是基于小分子凋亡诱导剂作用于直接激活某些基本的或特定的凋亡机制而发挥抗肿瘤作用的理论，设计并发现的一个小分子Caspase-3激动剂，具备直接激活凋亡通路中的Caspase-3进而诱导肿瘤细胞凋亡的能力。化合物AA-2对白血病来源的癌细胞系显示出相当程度的杀伤作用，其IC50值在4-9μM之间。(参见：Jack T N,James AW.Direct Activationof the Apoptosis Machinery as a Mechanism to Target Cancer Cells.PNAS.2003,100,7533-7538.)。
为了进一步提高对癌细胞的抑制能力，立足于司马沙尼、AA-2共有的吲哚-2-酮药效结构单元，研究一种全新结构的化合物，开发有效的蛋白激酶抑制剂或凋亡诱导剂，对于发现分子靶向抗肿瘤药物意义重大。
发明内容
本发明的目的在于提供一种3-取代吲哚-2-酮化合物及其制备方法和应用。该类化合物对人外周血T淋巴源性白血病细胞Jurkat、肺癌细胞A549和结肠癌细胞HCT116具有一定的生长抑制活性，可用于制备抗肿瘤药物。
为实现上述目的，本发明采用下述技术方案：
在本发明的第一方面，本发明提供一种3-取代吲哚-2-酮化合物，具有如下式(I)、(II)或(III)所示结构：
其中，R1、R2独立地选自氢、卤素、氰基、三氟甲基或甲氧基；R3选自苯基、取代苯基、吡啶基、脂肪烃基或取代脂肪烃基。
根据本发明优选的，所述3-取代吲哚-2-酮化合物包含其几何异构体，如顺式构型和反式构型。
根据本发明优选的，R1、R2独立地选自氢、F、Cl、Br、I、三氟甲基、氰基或甲氧基；优选的，R1、R2独立地选自氢、F、Cl、Br、三氟甲基、氰基或甲氧基。
根据本发明优选的，R3选自苯基、吡啶基、
根据本发明优选的，所述3-取代吲哚-2-酮化合物选自以下化合物：
(Z)-1-(3-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-1)；
(Z)-1-(4-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-2)；
(Z)-1-(3-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-3)；
(Z)-1-(4-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-4)；
(Z)-1-(3-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-5)；
(Z)-1-(4-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-6)；
(Z)-1-(3-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-7)；
(Z)-1-(4-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-8)；
(Z)-1-(3-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-9)；
(Z)-1-(4-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-10)；
(Z)-1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-11)；
(Z)-1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-12)；
(Z)-1-(3,4-二甲氧基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-13)；
(Z)-1-(3-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-1)；
(Z)-1-(4-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-2)；
(Z)-1-(3-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-3)；
(Z)-1-(4-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-4)；
(Z)-1-(3-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-5)；
(Z)-1-(4-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-6)；
(Z)-1-(3-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-7)；
(Z)-1-(4-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-8)；
(Z)-1-(3-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-9)；
(Z)-1-(4-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-10)；
(Z)-1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-11)；
(Z)-1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-12)；
(Z)-1-(3,4-二甲氧基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-13)；
(Z)-3-氟-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-1)；
(Z)-4-氟-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-2)；
(Z)-3-氯-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-3)；
(Z)-3-溴-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-4)；
(Z)-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-5)；
(Z)-4-甲氧基-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-6)；
(Z)-3-甲基-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-7)；
(Z)-4-甲基-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-8)；
(Z)-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)吡啶甲酰胺(III-9)；
(Z)-2-氯-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)乙酰胺(III-10)；
(Z)-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)环丙甲酰胺(III-11)；
(Z)-3-氟-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-12)；
(Z)-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-13)；
(Z)-3-甲基-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-14)；
(Z)-2-氯-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)乙酰胺(III-15)；
或，(Z)-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)环丙甲酰胺(III-16)；
在本发明的第二方面，提供上述3-取代吲哚-2-酮化合物的制备方法，合成路线如下所示：
其中，R1、R2独立地选自氢、卤素、氰基、三氟甲基或甲氧基；R3选自苯基、取代苯基、吡啶基、脂肪烃基或取代脂肪烃基。
根据本发明优选的，所述3-取代吲哚-2-酮化合物的制备方法，包括步骤：
以2-吲哚酮即化合物1为起始原料，与3,5-二甲基-1H-吡咯-2-甲醛经羟醛缩合反应生成中间体2；中间体2在K2CO3存在的条件下与取代苄氯或取代苄溴经亲核取代反应得式(I)化合物。
或者，以2-吲哚酮即化合物1为起始原料，经硝化反应生成中间体3；中间体3与3,5-二甲基-1H-吡咯-2-甲醛经羟醛缩合反应生成中间体4；中间体4在K2CO3存在的条件下与取代苄氯或取代苄溴经亲核取代反应生成中间体5；中间体5经铁粉还原得式(II)化合物；
或者，所得式(II)化合物与相应的羧酸经酰胺缩合反应，或在K2CO3存在的条件下与相应的酰氯经酰氯化反应得式(III)化合物。
本发明优选的实施方式中，可通过下述合成路线制备：
其中，R3选自苯基、吡啶基、
上述合成路线的试剂及条件：(a)3,5-二甲基-1H-吡咯-2-甲醛，哌啶，无水乙醇，N2,90℃,3h；(b)K2CO3,DMF,室温-80℃,3-5h；(c)发烟硝酸，浓硫酸，0℃-室温,2h；(d)3,5-二甲基-1H-吡咯-2-甲醛，哌啶，无水乙醇，N2,90℃,3h；(e)K2CO3,DMF,室温-80℃,3h；(f)Fe,NH4Cl,乙醇：水体积比＝3∶1,85℃,7h；(g)HBTU(O-苯并三氮唑-四甲基脲六氟磷酸酯),DIEA(N,N-二异丙基乙胺),DMF,0℃-室温,12h；或者，K2CO3,DMF,室温，12h。
进一步地，本发明优选的实施方式中，具体制备方法包括：
(1)将化合物1和3,5-二甲基-1H-吡咯-2-甲醛加入到茄形瓶中，加入无水乙醇作溶剂，室温搅拌下滴入3-5滴无水哌啶；滴毕，氮气保护，将反应体系转移至90℃油浴回流反应3h；待反应液自然冷却至室温，抽滤，滤饼用无水乙醇洗涤，干燥，得中间体2。
(2)将中间体2和K2CO3加入到茄形瓶中，用DMF作溶剂，室温搅拌30min后，再缓慢滴入取代苄氯或取代苄溴至反应液中，之后将反应体系转移至80℃油浴反应3-5h；冷却至室温，向反应液中倒入温度为15-20℃的冷水，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，抽滤，减压蒸除溶剂，所得产品经薄层层析纯化或用甲醇重结晶，得目标化合物I-1至I-13。
或者，
(3)将化合物1加入到茄形瓶中，搅拌下缓慢加入浓硫酸至溶解；在0℃冰浴条件下逐滴滴加发烟硝酸，滴毕，继续在0℃冰浴条件下反应20min，之后撤除冰浴，室温下反应2h；将反应液倒入冰水中，抽滤，滤饼水洗，干燥，得中间体3。
(4)将中间体3和3,5-二甲基-1H-吡咯-2-甲醛加入到茄形瓶中，加入无水乙醇作溶剂，室温搅拌下滴入3-5滴无水哌啶；滴毕，氮气保护，将反应体系转移至90℃油浴回流反应3h；待反应液自然冷却至室温，抽滤，滤饼用无水乙醇洗涤，干燥，得中间体4。
(5)将中间体4和K2CO3加入到茄形瓶中，用DMF作溶剂，室温搅拌30min后，再缓慢滴入取代苄氯或取代苄溴至反应液中，之后将反应体系转移至80℃油浴反应3h；冷却至室温，向反应液中倒入15℃-20℃的冷水，乙酸乙酯萃取，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，抽滤，减压蒸除溶剂，所得固体用甲醇重结晶，得中间体5。
(6)将中间体5，活化后的还原性铁粉和氯化铵加入到茄形瓶中，以CH3CH2OH和H2O的混合液作溶剂，85℃油浴回流反应7h；反应液用硅藻土趁热抽滤，浓缩滤液，饱和食盐水洗涤，无水硫酸钠干燥，抽滤，减压蒸除溶剂，硅胶柱层析，得目标化合物II-1至II-13。
或者，
(7)称取苯甲酸或取代苯甲酸或吡啶甲酸和HBTU加入到茄形瓶中，加入DMF至溶解，反应体系在冰浴条件下搅拌至0℃后，逐滴滴加DIEA至反应液中，搅拌40min，溶液颜色由无色渐变成红棕色或黄棕色；化合物II-11或II-12用DMF溶解后逐滴滴入反应液中，滴毕，撤除冰浴，室温反应12h；将反应液倒入装有温度为0℃冰水的烧杯中，析出大量黄色固体，抽滤，水洗，干燥，得黄色固体粗品；所得固体粗品用乙酸乙酯打浆洗涤两次，再用甲醇超声洗涤，抽滤，干燥，得目标化合物III-1至III-9，III-12至III-14。
或者，
(8)称取化合物II-11或II-12加入到茄形瓶中，用DMF溶解，加入K2CO3，室温下搅拌30min后缓慢滴入氯乙酰氯或环丙甲酰氯，滴毕，室温反应12h；将反应液倒入装有温度为0℃冰水的烧杯中，抽滤，水洗，干燥，得黄色固体粗品；所得固体粗品用乙酸乙酯打浆洗涤，再用甲醇超声洗涤，抽滤，干燥，得目标化合物III-10、III-11、III-15、III-16。
在本发明的第三方面，提供一种药物组合物，其包含上述第一方面中所述的3-取代吲哚-2-酮化合物或其药学上可接受的盐。
本发明所述“组合物”指包括治疗有效量的规定成分的药物产品，以及直接或间接地由规定量的规定成分的组合产生的任何产品。
在本发明的第四方面，提供一种药物制剂，其包含上述第一方面中所述的3-取代吲哚-2-酮化合物或其药学上可接受的盐和至少一种药学上可接受的辅料或载体。
本发明的3-取代吲哚-2-酮化合物或含有它的药物组合物或药物制剂可以单位剂量形式给药。给药剂型可以是液体剂型、固体剂型。液体剂型可以是真溶液类、胶体类、微粒剂型、乳剂剂型、混旋剂型。其他剂型例如片剂、胶囊、滴丸、气雾剂、丸剂、粉剂、溶液剂、混悬剂、乳剂、颗粒剂、栓剂、冻干粉针剂、包合物、填埋剂、贴剂、擦剂等。
本发明的药物组合或药物制剂中还可以含有常用的载体，这些载体包括但不局限于：离子交换剂、氧化铝、硬脂酸铝、卵磷脂、血清蛋白如人血清蛋白、缓冲物质(如磷酸盐、甘油、山梨酯、山梨酸钾、饱和植物脂肪酸的部分甘油酯混合物、水、盐)或电解质、硫酸鱼精蛋白、磷酸氢二钠、磷酸氢钾、氯化钠、锌盐、胶态氧化硅、三硅酸镁、聚乙烯吡咯烷酮、纤维素物质、聚乙二醇、羧甲基纤维素钠、聚丙烯酸酯、蜂蜡、羊毛酯等。载体在药物组合物或药物制剂中的含量可以是1wt％-98wt％，通常大约占到80wt％。为方便起见，局部麻醉剂、防腐剂、缓冲剂等可直接溶于载体中。
所述药学上可接受的辅料，包括但不限于赋形剂，所述赋形剂可以为粘合剂、填充剂、润滑剂、崩解剂、缓冲剂、稳定剂、防腐剂等等。所述辅料指药物组合物或药物制剂中除有效成分之外的成分，其对受试者无毒，且与药物活性成分可稳定共存或采用适当手段后稳定共存。
口服片剂和胶囊可以含有粘合剂，比如糖浆、***胶、山梨醇、黄芪胶或聚乙烯吡咯烷酮；可以含有填充剂，比如乳糖、蔗糖、玉米淀粉、磷酸钙、山梨醇、氨基乙酸；可以含有润滑剂，如硬脂酸镁，滑石，聚乙二醇，硅土；可以含有崩解剂，如马铃薯淀粉，或可接受的增润剂，如月桂醇钠硫酸盐。片剂可以用制药学上公知的方法包衣。
口服液可以制成水和油的悬浮液，溶液，乳浊液，糖浆，也可以制成干品，用前补充水或其它合适的媒质。这种液体制剂可以包含常规的添加剂，如悬浮剂：山梨醇、纤维素甲醚、葡萄糖糖浆、凝胶、羟乙基纤维素、羧甲基纤维素、硬脂酸铝凝胶、氢化的食用油脂，如乳化剂：卵磷脂、山梨聚糖单油酸盐、***树胶；或包含非水载体(可能包含可食用油)，如杏仁油、油脂如甘油、乙二醇、或乙醇；防腐剂，如对羟基苯甲酸甲酯或丙酯，山梨酸。如需要可添加调味剂或着色剂。
栓剂可包含常规的栓剂基质，如可可黄油或其它甘油酯。
对于胃肠外投药，液态剂型通常由化合物和一种消毒的载体制成。载体首选水。依照所选载体和药物浓度的不同，化合物既可溶于载体中也可制成悬浮溶液，在制成注射用溶液时先将化合物溶于水中，过滤消毒后装入封口瓶或安瓿中。
在本发明的第五方面，提供上述第一方面中所述3-取代吲哚-2-酮化合物或上述第三方面中所述的药物组合物或上述第四方面中所述的药物制剂在制备人外周血T淋巴源性白血病细胞、肺癌细胞和/或结肠癌细胞生长抑制剂中的应用。
根据本发明优选的，所述人外周血T淋巴源性白血病细胞为Jurkat，所述肺癌细胞为A549，结肠癌细胞为HCT116。
在本发明的第六方面，提供上述第一方面中所述3-取代吲哚-2-酮化合物或上述第三方面中所述的药物组合物或上述第四方面中所述的药物制剂在制备抗肿瘤药物中的应用。
根据本发明优选的，所述肿瘤为白血病、肺癌或结肠癌。
以及，本发明还提供了一种***的方法，其包括向受试者施用治疗有效剂量的上述第一方面中所述的3-取代吲哚-2-酮化合物或上述第三方面中所述的药物组合物或上述第四方面中所述的药物制剂，所述肿瘤尤其指白血病、肺癌或结肠癌；所述受试者术语是指已经是治疗、观察或实验的对象的动物，优选指哺乳动物，最优选指人。所述“治疗有效量”是指包括本发明化合物在内的活性化合物或药剂的量，该量可引起研究者、兽医、医生或其他医疗人员所追求的组织***、动物或人的生物学或医学响应，这包括减轻或部分减轻受治疗的疾病、综合征、病症或障碍的症状。必须认识到，本发明所述活性成分的最佳给药剂量和间隔是由其性质和诸如给药的形式、路径和部位以及所治疗的特定哺乳动物等外部条件决定的，而这一最佳给药剂量可用常规的技术确定。同时也必须认识到，最佳的疗程，即同时化合物在额定的时间内每日的剂量，可用本领域内公知的方法确定。
本发明具有以下有益效果：
本发明所述的3-取代吲哚-2-酮化合物对人外周血T淋巴源性白血病细胞Jurkat、肺癌细胞A549、结肠癌细胞HCT116呈现出低微摩尔浓度的生长抑制活性，能够实现对上述癌细胞的有效抑制，能够用于抗肿瘤药物的制备。
相比药物司马沙尼(SU5416)，本发明I-3、I-9、I-13、Ⅱ-2、Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12、III-9对Jurkat细胞的生长抑制活性更优；其中Ⅱ-2、Ⅱ-3、Ⅱ-5、Ⅱ-10、Ⅱ-11和III-9对Jurkat细胞的生长抑制活性大于50％。Ⅱ-3、Ⅱ-5、Ⅱ-10、Ⅱ-11和III-9对Jurkat、A549或HCT116细胞呈现出低微摩尔浓度(小于8.5μM)的生长抑制活性；其中，Ⅱ-5对Jurkat和A549细胞的生长抑制活性优于阳性化合物AA-2(1-(3,4-二氯苄基)-1H-吲哚-2,3-二酮)，而Ⅱ-11对Jurkat、A549和HCT116三株细胞系的生长抑制活性均优于阳性化合物AA-2。
具体实施方式
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件或按照制造厂商所建议的条件。
除非另行定义，文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外，任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
实施例1、中间体2的制备
称取2-吲哚酮(0.60g,4.51mmol)和3,5-二甲基-1H-吡咯-2-甲醛(0.67g,5.41mmol)加入到茄形瓶(100mL)中，加入10mL无水乙醇作溶剂，室温搅拌下滴入3-5滴无水哌啶。滴毕，氮气保护，将反应体系转移至90℃油浴回流反应3h。待反应液自然冷却至室温，有大量黄色絮状固体析出。抽滤，滤饼用少量0℃冷无水乙醇洗涤两次，干燥，称重得橙黄色絮状固体0.99g，收率92.5％。所得产物的核磁数据如下：1H NMR(400MHz,DMSO-d6)δ13.36(s,1H),10.77(s,1H),7.71(d,J＝7.5Hz,1H),7.56(s,1H),7.10(t,J＝7.6Hz,1H),6.97(t,J＝7.5Hz,1H),6.87(d,J＝7.6Hz,1H),6.02(s,1H),2.32(s,3H),2.30(s,3H).
实施例2、中间体3的制备
称取2-吲哚酮(1.00g,7.51mmol)加入到茄形瓶(250mL)中，搅拌下缓慢加入质量浓度为98％的浓硫酸(20mL)至溶解。在0℃冰浴条件下逐滴滴加发烟硝酸(615.21mg,9.76mmol)，滴毕，继续在0℃冰浴条件下反应20min，之后撤除冰浴，室温下反应2h。将反应液倒入250mL冰水中，析出大量棕黄色固体。抽滤，滤饼水洗三次，干燥，称重得棕黄色固体1.12g，收率83.6％。所得产物的核磁数据如下：1H NMR(400MHz,DMSO-d6)δ11.06(s,1H),8.16(d,J＝8.6Hz,1H),8.10(s,1H),6.99(d,J＝8.6Hz,1H),3.64(s,2H).
实施例3、中间体4的制备
称取中间体3(1.00g,5.62mmol)和3,5-二甲基-1H-吡咯-2-甲醛(0.83g,6.74mmol)加入到茄形瓶(100mL)中，加入20mL无水乙醇作溶剂，室温搅拌下滴入3-5滴无水哌啶。滴毕，氮气保护，将反应体系转移至90℃油浴回流反应3h。待反应液自然冷却至室温，有大量红棕色固体析出。抽滤，滤饼用少量0℃冷无水乙醇洗涤两次，干燥，称重得红棕色固体1.49g，收率93.7％。所得产物的核磁数据如下：1H NMR(400MHz,DMSO-d6)δ13.35(s,1H),11.43(s,1H),8.78(s,1H),8.03(d,J＝8.6Hz,1H),7.95(s,1H),7.03(d,J＝8.6Hz,1H),6.10(s,1H),2.37(s,3H),2.36(s,3H).
实施例4、中间体5(A-M)的制备
称取中间体4(1equiv)和K2CO3粉末(2.5equiv)加入到茄形瓶(100mL)中，用DMF(10mL)作溶剂，室温搅拌30min后，再缓慢滴入取代苄氯(1.2equiv)或取代苄溴(1.2equiv)至反应液中，之后将反应体系转移至80℃油浴反应3h。冷却至室温，向反应液中倒入冷水(15℃-20℃)100mL，乙酸乙酯萃取(10mL×3)，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，抽滤，减压蒸除溶剂，所得固体用甲醇重结晶，得中间体5(A-M)。
(Z)-1-(3-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5A)
棕黄色固体，产率78.9％。1H NMR(400MHz,DMSO-d6)δ13.27(s,1H),8.88(d,J＝2.2Hz,1H),8.06(dd,J＝8.0,2.9Hz,2H),7.39(d,J＝6.2Hz,1H),7.24(d,J＝8.7Hz,1H),7.20–7.08(m,4H),6.16(s,1H),5.22(s,2H),2.41(s,3H),2.39(s,3H).
(Z)-1-(4-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5B)
棕黄色固体，产率83.6％。1H NMR(400MHz,DMSO-d6)δ13.29(s,1H),8.87(d,J＝2.2Hz,1H),8.05(dd,J＝8.2,2.7Hz,2H),7.38(dd,J＝8.5,5.5Hz,2H),7.25(d,J＝8.7Hz,1H),7.17(t,J＝8.9Hz,2H),6.15(s,1H),5.18(s,2H),2.41(s,3H),2.39(s,3H).
(Z)-1-(3-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5C)
棕绿色固体，产率72.9％。1H NMR(400MHz,DMSO-d6)δ13.27(s,1H),8.89(d,J＝2.2Hz,1H),8.07(dd,J＝8.4,2.4Hz,2H),7.41(s,1H),7.37(d,J＝6.6Hz,2H),7.29–7.23(m,2H),6.16(s,1H),5.22(s,2H),2.42(s,3H),2.39(s,3H).
(Z)-1-(4-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5D)
棕绿色固体，产率75.1％。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),8.85(d,J＝2.2Hz,1H),8.04(dd,J＝7.7,3.2Hz,2H),7.40(d,J＝8.5Hz,2H),7.34(d,J＝8.5Hz,2H),7.21(d,J＝8.7Hz,1H),6.14(s,1H),5.18(s,2H),2.40(s,3H),2.38(s,3H).
(Z)-1-(3-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5E)
棕黄色固体，产率78.3％。1H NMR(400MHz,DMSO-d6)δ13.26(s,1H),8.89(d,J＝2.2Hz,1H),8.07(dd,J＝7.9,2.9Hz,2H),7.55(s,1H),7.49(d,J＝7.1Hz,1H),7.33–7.24(m,3H),6.16(s,1H),5.21(s,2H),2.42(s,3H),2.39(s,3H).
(Z)-1-(4-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5F)
棕黄色固体，产率75.8％。1H NMR(400MHz,DMSO-d6)δ13.27(s,1H),8.88(d,J＝2.2Hz,1H),8.08–8.03(m,2H),7.54(d,J＝8.4Hz,2H),7.28(d,J＝8.4Hz,2H),7.22(d,J＝8.7Hz,1H),6.16(s,1H),5.18(s,2H),2.41(s,3H),2.39(s,3H).
(Z)-1-(3-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5G)
棕黄色固体，产率80.6％。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),8.89(d,J＝2.2Hz,1H),8.09–8.04(m,2H),7.84(s,1H),7.77(d,J＝7.5Hz,1H),7.61(d,J＝8.0Hz,1H),7.56(t,J＝7.7Hz,1H),7.27(s,1H),6.16(s,1H),5.26(s,2H),2.42(s,3H),2.39(s,3H).
(Z)-1-(4-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5H)
棕黄色固体，产率77.1％。1H NMR(400MHz,DMSO-d6)δ13.24(s,1H),8.89(s,1H),8.05(d,J＝11.7Hz,2H),7.82(d,J＝7.8Hz,2H),7.48(d,J＝7.8Hz,2H),7.22(d,J＝8.7Hz,1H),6.16(s,1H),5.30(s,2H),2.41(s,3H),2.38(s,3H).
(Z)-1-(3-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5I)
棕红色固体，产率78.9％。1H NMR(400MHz,DMSO-d6)δ13.24(s,1H),8.88(d,J＝2.2Hz,1H),8.06(dd,J＝8.4,2.2Hz,2H),7.74(s,1H),7.66(d,J＝7.6Hz,1H),7.57(dd,J＝14.1,6.5Hz,2H),7.26(d,J＝8.7Hz,1H),6.15(s,1H),5.31(s,2H),2.41(s,3H),2.38(s,3H).
(Z)-1-(4-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5J)
棕红色固体，产率80.9％。1H NMR(400MHz,DMSO-d6)δ13.26(s,1H),8.90(d,J＝2.2Hz,1H),8.09–8.04(m,2H),7.72(d,J＝8.2Hz,2H),7.51(d,J＝8.1Hz,2H),7.23(d,J＝8.7Hz,1H),6.16(s,1H),5.31(s,2H),2.42(s,3H),2.38(s,3H).
(Z)-1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5K)
棕黄色固体，产率76.8％。1H NMR(400MHz,DMSO-d6)δ13.26(s,1H),8.88(d,J＝2.2Hz,1H),8.06(dd,J＝7.8,3.1Hz,2H),7.49–7.36(m,3H),7.27(d,J＝8.7Hz,1H),6.16(s,1H),5.19(s,2H),2.41(s,3H),2.39(s,3H).
(Z)-1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5L)
棕绿色固体，产率81.8％。1H NMR(400MHz,DMSO-d6)δ13.24(s,1H),8.88(s,1H),8.06(s,2H),7.64(s,1H),7.60(d,J＝8.0Hz,1H),7.25(d,J＝8.7Hz,2H),6.15(s,1H),5.21(s,2H),2.41(s,3H),2.38(s,3H).
(Z)-1-(3,4-二甲氧基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-硝基-2-吲哚酮(5M)
棕红色固体，产率79.1％。1H NMR(400MHz,DMSO-d6)δ13.31(s,1H),8.86(s,1H),8.05(s,2H),7.23(d,J＝8.7Hz,1H),7.03(s,1H),6.87(d,J＝8.2Hz,1H),6.76(d,J＝8.5Hz,1H),6.15(s,1H),5.11(s,2H),3.72(s,3H),3.69(s,3H),2.40(s,3H),2.39(s,3H).
实施例5、目标化合物I-1至I-13的制备
称取中间体2(1equiv)和K2CO3粉末(2.5equiv)加入到茄形瓶(100mL)中，用DMF(10mL)作溶剂，室温搅拌30min后，再缓慢滴入取代苄氯(1.2equiv)或取代苄溴(1.2equiv)至反应液中，之后将反应体系转移至80℃油浴反应3-5h。冷却至室温，向反应液中倒入冷水(15℃-20℃)100mL，乙酸乙酯萃取(10mL×3)，合并有机相，饱和食盐水洗涤，无水硫酸钠干燥，抽滤，减压蒸除溶剂，所得产品经薄层层析纯化(展开体系为石油醚∶乙酸乙酯体积比2∶1)，或用甲醇重结晶，得目标化合物I-1至I-13。
(Z)-1-(3-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-1)
橙黄色固体，产率71.2％，Mp：180-181℃。1H NMR(400MHz,DMSO-d6)δ13.27(s,1H),7.81(d,J＝7.5Hz,1H),7.67(s,1H),7.41–7.35(m,1H),7.14(dd,J＝14.6,7.5Hz,4H),7.08–7.05(m,1H),7.01(t,J＝6.6Hz,1H),6.06(s,1H),5.12(s,2H),2.35(s,3H),2.34(s,3H).13C NMR(100MHz,CDCl3)δ168.28(s),163.12(d,J＝246.6Hz),139.14(d,J＝7.0Hz),138.60(s),137.02(s),132.73(s),130.31(d,J＝8.3Hz),127.12(s),125.66(s),125.53(s),123.51(s),122.56(d,J＝2.9Hz),121.83(s),117.17(s),114.41(d,J＝21.2Hz),114.01(d,J＝22.0Hz),112.72(s),111.20(s),108.49(s),43.15(s),13.97(s),11.67(s).HRMS(ESI):calcd for C22H19FN2O[M+H]+347.1481,found 347.1533。
(Z)-1-(4-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-2)
橙黄色固体，产率70.2％，Mp：236-238℃。1H NMR(400MHz,DMSO-d6)δ13.29(s,1H),7.80(d,J＝7.4Hz,1H),7.66(s,1H),7.38(dd,J＝8.4,5.6Hz,2H),7.17(d,J＝8.8Hz,2H),7.11(d,J＝7.0Hz,1H),7.03(dd,J＝14.8,7.5Hz,2H),6.06(s,1H),5.08(s,2H),2.36(s,3H),2.33(s,3H).13C NMR(100MHz,CDCl3)δ168.28(s),144.29(d,J＝490.5Hz),138.66(s),136.95(s),132.67(d,J＝2.8Hz),132.25(d,J＝3.0Hz),128.77(s),128.69(s),127.09(d,J＝3.4Hz),125.67(s),125.54(d,J＝5.1Hz),123.45(s),121.77(s),117.16(s),115.64(d,J＝21.6Hz),112.70(s),111.33(s),108.53(s),42.97(s),13.97(s),11.67(s).HRMS(ESI):calcd for C22H19FN2O[M+H]+347.1481,found 347.1535。
(Z)-1-(3-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-3)
橙黄色固体，产率64.4％，Mp：120-122℃。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),7.81(d,J＝7.4Hz,1H),7.67(s,1H),7.37(d,J＝10.8Hz,3H),7.27(d,J＝7.0Hz,1H),7.13(t,J＝7.4Hz,1H),7.06(d,J＝7.4Hz,1H),7.02(t,J＝6.3Hz,1H),6.06(s,1H),5.11(s,2H),2.35(s,3H),2.34(s,3H).13C NMR(100MHz,CDCl3)δ168.29(s),138.66(s),138.58(s),137.05(s),134.70(s),132.76(s),130.05(s),127.72(s),127.16(s),125.68(s),125.56(s),125.18(s),123.53(s),121.86(s),117.19(s),112.74(s),111.19(s),108.48(s),43.15(s),13.97(s),11.67(s).HRMS(ESI):calcd for C22H19ClN2O[M+H]+363.1186,found363.1230。
(Z)-1-(4-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-4)
橙黄色固体，产率68.3％，Mp：127-130℃。1H NMR(400MHz,DMSO-d6)δ13.27(s,1H),7.81(d,J＝7.3Hz,1H),7.67(s,1H),7.40(d,J＝8.5Hz,2H),7.34(d,J＝8.5Hz,2H),7.12(t,J＝7.1Hz,1H),7.04(t,J＝7.1Hz,1H),6.99(d,J＝7.7Hz,1H),6.06(s,1H),5.09(s,2H),2.35(s,3H),2.33(s,3H).13C NMR(100MHz,CDCl3)δ168.28(s),138.59(s),137.01(s),135.06(s),133.26(s),132.73(s),128.93(s),128.45(s),127.12(s),125.68(s),125.53(s),123.49(s),121.82(s),117.18(s),112.73(s),111.25(s),108.50(s),43.03(s),13.97(s),11.67(s).HRMS(ESI):calcd for C22H19ClN2O[M+H]+363.1186,found 363.1241。
(Z)-1-(3-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-5)
橙红色固体，产率73.7％，Mp：149-151℃。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),7.81(d,J＝7.3Hz,1H),7.67(s,1H),7.52(s,1H),7.49–7.44(m,1H),7.30(d,J＝5.0Hz,2H),7.13(t,J＝7.2Hz,1H),7.05(d,J＝7.5Hz,1H),7.01(t,J＝5.6Hz,1H),6.06(s,1H),5.10(s,2H),2.35(s,3H),2.33(s,3H).13C NMR(100MHz,CDCl3)δ168.26(s),138.92(s),138.55(s),137.04(s),132.75(s),130.66(s),130.33(s),130.05(s),127.12(s),125.67(s),125.64(s),125.55(s),123.51(s),122.88(s),121.85(s),117.18(s),112.74(s),111.17(s),108.47(s),43.09(s),13.98(s),11.67(s).HRMS(ESI):calcd for C22H19BrN2O[M+H]+407.0681,found 407.0742。
(Z)-1-(4-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-6)
橙红色固体，产率69.1％，Mp：180-181℃。1H NMR(400MHz,DMSO-d6)δ13.26(s,1H),7.80(d,J＝7.4Hz,1H),7.66(s,1H),7.53(d,J＝8.4Hz,2H),7.28(d,J＝8.3Hz,2H),7.11(t,J＝7.5Hz,1H),7.03(t,J＝7.2Hz,1H),6.98(d,J＝7.8Hz,1H),6.05(s,1H),5.07(s,2H),2.35(s,3H),2.33(s,3H).13C NMR(100MHz,CDCl3)δ168.26(s),138.55(s),137.00(s),135.57(s),132.73(s),131.86(s),128.78(s),127.11(s),125.66(s),125.51(s),123.48(s),121.82(s),121.32(s),117.17(s),112.73(s),111.21(s),108.48(s),43.07(s),13.97(s),11.67(s).HRMS(ESI):calcd for C22H19BrN2O[M+H]+407.0681,found 407.0749。
(Z)-1-(3-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-7)
橙黄色固体，产率82.3％，Mp：171-173℃。1H NMR(400MHz,DMSO-d6)δ13.24(s,1H),7.82(d,J＝2.9Hz,2H),7.75(d,J＝7.5Hz,1H),7.67(s,1H),7.62(d,J＝7.9Hz,1H),7.55(t,J＝7.7Hz,1H),7.13(t,J＝7.5Hz,1H),7.04(dd,J＝15.2,7.6Hz,2H),6.06(s,1H),5.15(s,2H),2.35(s,3H),2.33(s,3H).13C NMR(100MHz,CDCl3)δ168.26(s),138.31(s),138.18(s),137.35(s),133.16(s),131.53(s),131.27(s),130.65(s),129.63(s),127.19(s),125.75(s),125.54(s),123.78(s),122.06(s),118.59(s),117.33(s),112.98(s),112.91(s),110.77(s),108.17(s),42.94(s),13.99(s),11.69(s).HRMS(ESI):calcd forC23H19N3O[M+H]+354.1528,found 354.1590。
(Z)-1-(4-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-8)
橙黄色固体，产率79.6％，Mp：194-196℃。1H NMR(400MHz,DMSO-d6)δ13.23(s,1H),7.84–7.77(m,3H),7.68(s,1H),7.48(d,J＝8.2Hz,2H),7.11(t,J＝7.5Hz,1H),7.05(t,J＝7.3Hz,1H),6.98(d,J＝7.7Hz,1H),6.06(s,1H),5.19(s,2H),2.34(s,3H),2.33(s,3H).13CNMR(100MHz,CDCl3)δ168.27(s),142.09(s),138.23(s),137.34(s),133.17(s),132.63(s),127.67(s),127.18(s),125.72(s),125.53(s),123.59(s),122.07(s),118.63(s),117.31(s),112.97(s),111.47(s),110.77(s),108.23(s),43.30(s),13.98(s),11.68(s).HRMS(ESI):calcd for C23H19N3O[M+H]+354.1528,found 354.1592。
(Z)-1-(3-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-9)
橙黄色固体，产率80.5％，Mp：126-128℃。1H NMR(400MHz,CDCl3)δ13.18(s,1H),7.59(s,1H),7.52(t,J＝6.8Hz,2H),7.47–7.38(m,3H),7.13–7.03(m,2H),6.73(d,J＝8.0Hz,1H),6.00(s,1H),5.13(s,2H),2.39(s,3H),2.35(s,3H).13C NMR(100MHz,CDCl3)δ168.33(s),138.49(s),137.67(s),137.14(s),132.87(s),131.29(s),130.97(s),130.32(s),129.33(s),127.15(s),125.71(s),125.56(s),124.41(dd,J＝7.6,3.7Hz),123.91(dd,J＝7.6,3.8Hz),123.61(s),121.92(s),117.24(s),112.79(s),111.07(s),108.37(s),43.29(s),13.97(s),11.67(s).HRMS(ESI):calcd for C23H19F3N2O[M+H]+397.1449,found 397.1501。
(Z)-1-(4-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-10)
橙黄色固体，产率75.7％，Mp：125-127℃。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),7.82(d,J＝7.5Hz,1H),7.74–7.68(m,3H),7.52(d,J＝8.0Hz,2H),7.12(t,J＝7.4Hz,1H),7.05(t,J＝7.4Hz,1H),6.99(d,J＝7.7Hz,1H),6.06(s,1H),5.20(s,2H),2.35(s,3H),2.34(s,3H).13C NMR(100MHz,CDCl3)δ168.31(s),140.63(s),138.45(s),137.16(s),132.92(s),129.96(s),129.63(s),128.85(s),127.27(s),127.15(s),125.76(dd,J＝7.8,4.0Hz),125.54(s),123.62(s),121.94(s),117.24(s),112.81(s),111.03(s),108.38(s),43.23(s),13.97(s),11.68(s).HRMS(ESI):calcd for C23H19F3N2O[M+H]+397.1449,found397.1503。
(Z)-1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-11)
橙红色固体，产率67.8％，Mp：117-118℃。1H NMR(400MHz,CDCl3)δ13.17(s,1H),7.52(d,J＝6.9Hz,1H),7.44(s,1H),7.14–7.02(m,5H),6.73(d,J＝6.9Hz,1H),6.00(s,1H),5.03(s,2H),2.39(s,3H),2.35(s,3H).13C NMR(100MHz,CDCl3)δ168.23(s),151.37(dd,J＝79.8,12.7Hz),148.90(dd,J＝78.5,12.9Hz),138.37(s),137.17(s),133.61(dd,J＝5.1,3.8Hz),132.93(s),127.14(s),125.70(s),125.52(s),123.62(s),123.01(dd,J＝6.4,3.6Hz),121.93(s),117.54(d,J＝17.4Hz),117.24(s),116.18(d,J＝17.8Hz),112.81(s),111.01(s),108.34(s),42.71(s),13.98(s),11.67(s).HRMS(ESI):calcd forC22H18F2N2O[M+H]+365.1387,found 365.1457。
(Z)-1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-12)
橙红色固体，产率72.7％，Mp：150-152℃。1H NMR(400MHz,CDCl3)δ13.16(s,1H),7.53(d,J＝6.9Hz,1H),7.45(s,1H),7.38(dd,J＝9.0,4.9Hz,2H),7.10(ddd,J＝21.8,11.2,4.5Hz,3H),6.72(d,J＝7.1Hz,1H),6.00(s,1H),5.03(s,2H),2.39(s,3H),2.35(s,3H).13CNMR(100MHz,CDCl3)δ168.23(s),138.31(s),137.23(s),136.91(s),132.99(s),132.91(s),131.60(s),130.76(s),129.04(s),127.15(s),126.45(s),125.70(s),125.56(s),123.67(s),121.98(s),117.26(s),112.84(s),110.94(s),108.33(s),42.66(s),13.99(s),11.69(s).HRMS(ESI):calcd for C22H18Cl2N2O[M+H]+397.0796,found397.0889。
(Z)-1-(3,4-二甲氧基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮(I-13)
橙黄色固体，产率65.1％，Mp：168-170℃。1H NMR(400MHz,CDCl3)δ13.25(s,1H),7.50(dd,J＝10.9,7.5Hz,1H),7.42(d,J＝15.5Hz,1H),7.08(dq,J＝13.8,7.5Hz,3H),6.92–6.75(m,4H),5.98(s,1H),5.03(s,2H),3.83(s,3H),3.82(s,3H),2.39(s,3H),2.34(s,3H).13CNMR(100MHz,CDCl3)δ168.32(s),149.30(s),148.44(s),138.99(s),136.74(s),132.39(s),129.05(s),127.09(s),125.54(s),123.28(s),121.65(s),119.34(s),117.09(s),112.60(s),111.63(s),111.27(s),110.45(s),109.18(s),108.74(s),55.93(s),43.48(s),13.96(s),11.65(s).HRMS(ESI):calcd for C24H24N2O3[M+H]+389.1787,found389.1870。
实施例6、目标化合物II-1至II-13的制备
将还原铁粉(1equiv)与浓度为5wt％的盐酸(500mL)混合，室温搅拌30min后抽滤，用水冲洗铁粉直至洗脱液呈中性，将铁粉干燥后即得活化铁粉。称取中间体5(1equiv)，活化后的还原性铁粉(4equiv)和氯化铵(4equiv)加入到茄形瓶(100mL)中，以CH3CH2OH∶H2O体积比＝3∶1共24mL作溶剂，85℃油浴回流反应7h。反应液用硅藻土趁热抽滤，浓缩滤液，饱和食盐水洗涤，无水硫酸钠干燥，抽滤，减压蒸除溶剂。硅胶柱层析，洗脱***为石油醚∶乙酸乙酯体积比＝5∶1，得目标化合物II-1至II-13。
(Z)-1-(3-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-1)
鲜红色固体，产率54.1％，Mp：156-158℃。1H NMR(400MHz,DMSO-d6)δ13.30(s,1H),7.40(s,1H),7.39–7.34(m,1H),7.14–7.08(m,3H),6.98(d,J＝1.9Hz,1H),6.67(d,J＝8.2Hz,1H),6.38(dd,J＝8.2,1.9Hz,1H),6.02(s,1H),4.99(s,2H),4.70(s,2H),2.33(s,3H),2.29(s,3H).13C NMR(100MHz,DMSO-d6)δ167.67(s),162.69(d,J＝244.0Hz),144.48(s),140.72(d,J＝7.0Hz),136.23(s),132.01(s),131.11(d,J＝8.3Hz),130.07(s),126.80(s),125.96(s),123.62(s),123.17(s),114.64(s),114.46(d,J＝5.1Hz),114.26(s),112.82(d,J＝32.3Hz),112.42(s),109.63(s),104.81(s),42.71(s),13.95(s),11.73(s).HRMS(ESI):calcd for C22H20FN3O[M+H]+362.1590,found 362.1602。
(Z)-1-(4-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-2)
鲜红色固体，产率52.1％，Mp：110-112℃。1H NMR(400MHz,DMSO-d6)δ13.32(s,1H),7.40(s,1H),7.35(dd,J＝8.1,5.7Hz,2H),7.14(t,J＝8.8Hz,2H),6.98(s,1H),6.67(d,J＝8.2Hz,1H),6.39(d,J＝8.1Hz,1H),6.01(s,1H),4.96(s,2H),2.32(s,3H),2.29(s,3H),1.22(s,2H).13C NMR(100MHz,DMSO-d6)δ167.62(s),161.82(d,J＝243.0Hz),144.35(s),136.13(s),133.94(d,J＝2.9Hz),131.91(s),130.15(s),129.74(d,J＝8.2Hz),126.79(s),125.98(s),123.08(s),115.81(d,J＝21.4Hz),112.87(d,J＝15.9Hz),112.44(s),109.66(s),104.84(s),42.48(s),13.96(s),11.73(s).HRMS(ESI):calcd for C22H20FN3O[M+H]+362.1590,found 362.1605。
(Z)-1-(3-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-3)
鲜红色固体，产率57.6％，Mp：158-160℃。1H NMR(400MHz,DMSO-d6)δ13.29(s,1H),7.41(s,1H),7.39–7.31(m,3H),7.25(d,J＝7.1Hz,1H),6.98(d,J＝1.8Hz,1H),6.68(d,J＝8.2Hz,1H),6.39(dd,J＝8.2,1.9Hz,1H),6.02(s,1H),4.99(s,2H),4.70(s,2H),2.33(s,3H),2.29(s,3H).13C NMR(100MHz,DMSO-d6)δ167.67(s),144.57(s),140.40(s),136.22(s),133.64(s),132.00(s),131.03(s),130.00(s),127.72(s),127.36(s),126.80(s),126.32(s),125.95(s),123.19(s),112.98(s),112.65(s),112.39(s),109.62(s),104.80(s),42.64(s),13.98(s),11.75(s).HRMS(ESI):calcd for C22H20ClN3O[M+H]+378.1295,found 378.1338。
(Z)-1-(4-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-4)
鲜红色固体，产率55.8％，Mp：162-164℃。1H NMR(400MHz,DMSO-d6)δ13.32(s,1H),7.39(d,J＝8.2Hz,3H),7.32(d,J＝8.3Hz,2H),6.98(s,1H),6.65(d,J＝8.2Hz,1H),6.38(d,J＝8.1Hz,1H),6.02(s,1H),4.97(s,2H),4.69(s,2H),2.33(s,3H),2.29(s,3H).13CNMR(100MHz,DMSO-d6)δ167.64(s),144.52(s),136.81(s),136.12(s),132.27(s),131.89(s),130.04(s),129.57(s),129.03(s),126.80(s),125.97(s),123.10(s),112.94(s),112.77(s),112.37(s),109.64(s),104.79(s),42.54(s),13.98(s),11.74(s).HRMS(ESI):calcdfor C22H20ClN3O[M+H]+378.1295,found 378.1316。
(Z)-1-(3-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-5)
鲜红色固体，产率41.4％，Mp：108-110℃。1H NMR(400MHz,DMSO-d6)δ13.28(s,1H),7.46(d,J＝8.2Hz,2H),7.40(s,1H),7.32–7.26(m,2H),6.98(s,1H),6.67(d,J＝8.2Hz,1H),6.38(d,J＝8.1Hz,1H),6.01(s,1H),4.98(s,2H),4.69(s,2H),2.33(s,3H),2.29(s,3H).13C NMR(100MHz,DMSO-d6)δ167.65(s),144.55(s),140.64(s),136.22(s),132.00(s),131.30(s),130.61(s),130.22(s),129.98(s),126.79(s),126.68(s),125.94(s),123.18(s),122.25(s),112.98(s),112.63(s),112.39(s),109.62(s),104.80(s),42.58(s),13.98(s),11.75(s).HRMS(ESI):calcd for C22H20BrN3O[M+H]+422.0790,found 422.0801。
(Z)-1-(4-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-6)
鲜红色固体，产率46.4％，Mp：180-182℃。1H NMR(400MHz,DMSO-d6)δ13.31(s,1H),7.52(d,J＝8.3Hz,2H),7.40(s,1H),7.26(d,J＝8.3Hz,2H),6.99(d,J＝1.5Hz,1H),6.65(d,J＝8.2Hz,1H),6.39(d,J＝8.2Hz,1H),6.02(s,1H),4.96(s,2H),4.83(s,2H),2.33(s,3H),2.29(s,3H).13C NMR(100MHz,DMSO-d6)δ167.65(s),144.21(s),137.23(s),136.17(s),131.95(s),130.16(s),129.92(s),126.81(s),125.98(s),123.15(s),120.77(s),112.97(s),112.70(s),112.50(s),109.64(s),104.94(s),42.60(s),13.98(s),11.75(s).HRMS(ESI):calcd for C22H20BrN3O[M+H]+422.0790,found 422.0802。
(Z)-1-(3-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-7)
鲜红色固体，产率57.7％，Mp：178-180℃。1H NMR(400MHz,DMSO-d6)δ13.28(s,1H),7.75(d,J＝12.1Hz,2H),7.56(dt,J＝14.4,7.1Hz,2H),7.41(s,1H),6.98(s,1H),6.68(d,J＝8.3Hz,1H),6.38(d,J＝8.1Hz,1H),6.02(s,1H),5.04(s,2H),4.70(s,2H),2.33(s,3H),2.29(s,3H).13C NMR(100MHz,DMSO-d6)δ167.72(s),144.54(s),139.51(s),136.35(s),132.50(s),132.17(s),131.63(s),131.16(s),130.44(s),129.87(s),126.81(s),126.02(s),123.27(s),119.13(s),113.03(s),112.51(s),112.43(s),111.94(s),109.57(s),104.85(s),42.52(s),13.95(s),11.72(s).HRMS(ESI):calcd for C23H20N4O[M+H]+369.1637,found 369.1656。
(Z)-1-(4-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-8)
鲜红色固体，产率54.5％，Mp：190-191℃。1H NMR(400MHz,DMSO-d6)δ13.27(s,1H),7.80(d,J＝7.6Hz,2H),7.46(d,J＝7.5Hz,2H),7.41(s,1H),6.98(s,1H),6.64(d,J＝8.0Hz,1H),6.37(d,J＝7.9Hz,1H),6.02(s,1H),5.07(s,2H),4.70(s,2H),2.32(s,3H),2.29(s,3H).13C NMR(100MHz,DMSO-d6)δ167.72(s),144.59(s),143.62(s),136.31(s),133.04(s),132.14(s),129.91(s),128.47(s),126.82(s),126.00(s),123.27(s),119.19(s),113.02(s),112.52(s),112.39(s),110.49(s),109.56(s),104.83(s),42.95(s),13.95(s),11.74(s).HRMS(ESI):calcd for C23H20N4O[M+H]+369.1637,found 369.1645。
(Z)-1-(3-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-9)
鲜红色固体，产率52.3％，Mp：112-114℃。1H NMR(400MHz,DMSO-d6)δ13.29(s,1H),7.68(s,1H),7.64(d,J＝6.1Hz,1H),7.57(d,J＝6.0Hz,2H),7.42(s,1H),6.99(d,J＝1.6Hz,1H),6.69(d,J＝8.2Hz,1H),6.39(dd,J＝8.2,1.8Hz,1H),6.02(s,1H),5.09(s,2H),4.70(s,2H),2.33(s,3H),2.30(s,3H).13C NMR(100MHz,DMSO-d6)δ167.74(s),144.59(s),139.38(s),136.25(s),132.05(s),131.65(s),130.26(s),129.97(s),129.87(s),129.55(s),126.81(s),125.97(s),124.74–124.37(m),124.12(d,J＝3.8Hz),123.23(s),113.00(s),112.60(s),112.40(s),109.57(s),104.84(s),42.74(s),13.98(s),11.74(s).HRMS(ESI):calcd for C23H20F3N3O[M+H]+412.1558,found 412.1573。
(Z)-1-(4-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-10)
鲜红色固体，产率56.7％，Mp：160-162℃。1H NMR(400MHz,DMSO-d6)δ13.34(s,1H),7.75(d,J＝7.9Hz,2H),7.54(d,J＝7.8Hz,2H),7.46(s,1H),7.04(s,1H),6.70(d,J＝8.2Hz,1H),6.43(d,J＝7.7Hz,1H),6.06(s,1H),5.13(s,2H),4.75(s,2H),2.37(s,3H),2.34(s,3H).13C NMR(100MHz,DMSO-d6)δ167.71(s),144.60(s),142.65(s),136.20(s),132.01(s),130.00(s),128.51(s),128.32(s),128.19(s),126.82(s),126.68–125.83(m),123.35(s),123.24(d,J＝6.6Hz),112.98(s),112.66(s),112.39(s),109.58(s),104.82(s),42.83(s),13.97(s),11.75(s).HRMS(ESI):calcd for C23H20F3N3O[M+H]+412.1558,found 412.1564。
(Z)-1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-11)
鲜红色固体，产率53.6％，Mp：150-152℃。1H NMR(400MHz,DMSO-d6)δ13.29(s,1H),7.42–7.35(m,3H),7.14(d,J＝3.7Hz,1H),6.98(d,J＝1.8Hz,1H),6.69(d,J＝8.2Hz,1H),6.40(dd,J＝8.2,1.9Hz,1H),6.02(s,1H),4.97(s,2H),4.71(s,2H),2.33(s,3H),2.29(s,3H).13C NMR(100MHz,DMSO-d6)δ167.66(s),150.65(dd,J＝69.4,12.6Hz),148.21(dd,J＝68.3,12.6Hz),144.56(s),136.20(s),135.60(dd,J＝5.0,4.1Hz),131.99(s),129.91(s),126.81(s),125.98(s),124.46(dd,J＝6.5,3.4Hz),123.18(s),118.17(d,J＝17.2Hz),116.84(d,J＝17.3Hz),112.97(s),112.65(s),112.39(s),109.62(s),104.81(s),42.24(s),13.97(s),11.74(s).HRMS(ESI):calcd for C22H19F2N3O[M+H]+380.1496,found380.1516。
(Z)-1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-12)
鲜红色固体，产率61.6％，Mp：186-187℃。1H NMR(400MHz,DMSO-d6)δ13.27(s,1H),7.62–7.55(m,2H),7.41(s,1H),7.25(d,J＝8.2Hz,1H),6.98(s,1H),6.68(d,J＝7.8Hz,1H),6.39(d,J＝8.4Hz,1H),6.02(s,1H),4.99(s,2H),4.71(s,2H),2.33(s,3H),2.29(s,3H).13C NMR(100MHz,DMSO-d6)δ167.71(s),144.61(s),139.05(s),136.26(s),132.06(s),131.64(s),131.31(s),130.38(s),129.90(s),129.63(s),127.95(s),126.86(s),126.05(s),123.22(s),112.99(s),112.58(s),112.43(s),109.58(s),104.86(s),42.17(s),13.97(s),11.75(s).HRMS(ESI):calcd for C22H19Cl2N3O[M+H]+412.0905,found412.0926。
(Z)-1-(3,4-二甲氧基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮(II-13)
鲜红色固体，产率43.6％，Mp：110-111℃。1H NMR(400MHz,DMSO-d6)δ13.36(s,1H),7.39(s,1H),6.98(s,2H),6.87(d,J＝8.1Hz,1H),6.76(d,J＝7.9Hz,1H),6.68(d,J＝8.2Hz,1H),6.39(d,J＝8.0Hz,1H),6.01(s,1H),4.89(s,2H),3.71(s,3H),3.69(s,3H),2.33(s,3H),2.29(s,3H).13C NMR(100MHz,DMSO-d6)δ167.61(s),149.20(s),148.52(s),143.99(s),135.95(s),131.69(s),130.54(s),130.04(s),126.79(s),125.93(s),122.94(s),119.79(s),112.99(s),112.88(s),112.54(s),112.42(s),111.97(s),109.83(s),104.91(s),55.98(s),43.01(s),13.98(s),11.74(s).HRMS(ESI):calcd for C24H25N3O3[M+H]+404.1896,found 404.1922。
实施例7、目标化合物III-1至III-16的制备
称取苯甲酸或取代苯甲酸或吡啶甲酸(1.2equiv)和HBTU(1.2equiv)加入到茄形瓶(100mL)中，加入适量的DMF(10mL)至溶解，反应体系在冰浴条件下搅拌至0℃后，逐滴滴加DIEA(1.5equiv)至反应液中，搅拌40min，溶液颜色由无色渐变成红棕色或黄棕色。化合物II-11或II-12(1equiv)用10mL DMF溶解后逐滴滴入反应液中，滴毕，撤除冰浴，室温反应过夜。可观察到反应液中有固体生成，将反应液倒入装有冰水(温度0℃，100mL)的烧杯中，析出大量黄色固体，抽滤，水洗，干燥，得黄色固体粗品。所得固体粗品用少量乙酸乙酯打浆洗涤两次，再用少量甲醇超声洗涤，抽滤，干燥，得目标化合物III-1至III-9和III-12至III-14。
称取化合物II-11或II-12(1equiv)加入到茄形瓶(50mL)中，用适量的DMF(6mL)溶解，加入K2CO3粉末(1.2equiv)，室温下搅拌30min后缓慢滴入氯乙酰氯(1.2equiv)或环丙甲酰氯(1.2equiv)，滴毕，室温反应过夜(12h)。可观察到反应液中有固体生成，将反应液倒入装有冰水(0℃，100mL)的烧杯中，析出大量黄色固体，抽滤，水洗，干燥，得黄色固体粗品。所得固体粗品用少量乙酸乙酯打浆洗涤两次，再用少量甲醇超声洗涤，抽滤，干燥，得目标化合物III-10、III-11、III-15、III-16。
(Z)-3-氟-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-1)
橙黄色固体，产率75.1％，Mp：273-275℃。1H NMR(400MHz,DMSO-d6)δ13.26(s,1H),10.26(s,1H),8.07(s,1H),7.82(dd,J＝18.2,7.4Hz,2H),7.59(d,J＝20.0Hz,4H),7.45(d,J＝1.6Hz,2H),7.27(d,J＝6.1Hz,1H),7.10–6.98(m,1H),6.08(s,1H),5.11(s,2H),2.36(s,3H),2.33(s,3H).13C NMR(100MHz,DMSO-d6)δ168.07(s),164.24(s),162.44(d,J＝244.7Hz),138.75(s),137.61(d,J＝4.7Hz),135.19(s),133.81(s),133.55(s),131.67(s),131.43(s),131.06(d,J＝8.0Hz),130.48(s),129.70(s),127.94(s),127.09(s),125.41(s),124.26(d,J＝6.1Hz),119.78(d,J＝1.2Hz),118.96(s),118.76(s),114.93(s),114.69(s),113.58(s),112.29(s),111.12(s),109.04(s),42.25(s),14.05(s),11.81(s).HRMS(ESI):calcd for C29H22Cl2FN3O2[M+H]+534.1073,found 534.1169。
(Z)-4-氟-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-2)
橙黄色固体，产率66.3％，Mp：314-316℃。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),10.19(s,1H),8.06(d,J＝8.0Hz,3H),7.60(d,J＝8.1Hz,2H),7.56(s,1H),7.40(dd,J＝13.3,8.7Hz,3H),7.27(d,J＝8.3Hz,1H),7.02(d,J＝8.4Hz,1H),6.08(s,1H),5.11(s,2H),2.36(s,3H),2.33(s,3H).13C NMR(100MHz,DMSO-d6)δ167.01(s),164.63(d,J＝5.1Hz),163.49(d,J＝1.4Hz),156.93(s),137.68(s),136.44(s),134.03(s),132.93(s),132.40(s),130.59(s),130.34(s),129.66(s),129.57(s),129.39(s),128.62(s),126.86(s),126.01(s),124.31(s),123.17(d,J＝2.4Hz),118.73(d,J＝1.6Hz),114.82(s),114.60(s),112.47(s),111.25(d,J＝3.1Hz),110.12(s),107.94(s),41.20(s),12.97(s),10.73(s).HRMS(ESI):calcd for C29H22Cl2FN3O2[M+H]+534.1073,found 534.1127。
(Z)-3-氯-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-3)
橙黄色固体，产率59.9％，Mp：276-278℃。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),10.31(s,1H),8.05(d,J＝8.9Hz,2H),7.95(d,J＝7.3Hz,1H),7.67(d,J＝8.5Hz,1H),7.59(dd,J＝15.1,7.5Hz,4H),7.45(d,J＝7.6Hz,1H),7.27(d,J＝8.7Hz,1H),7.03(d,J＝8.3Hz,1H),6.08(s,1H),5.11(s,2H),2.36(s,3H),2.33(s,3H).13C NMR(100MHz,DMSO-d6)δ168.07(s),164.18(s),138.74(s),137.61(s),137.31(s),135.19(s),133.80(s),133.70(s),133.57(s),131.79(s),131.67(s),131.43(s),130.90(s),130.47(s),129.69(s),127.93(s),127.77(s),127.09(s),126.84(s),125.40(s),124.30(s),119.76(s),113.59(s),112.24(s),111.10(s),109.03(s),42.25(s),14.05(s),11.82(s).HRMS(ESI):calcdfor C29H22Cl3N3O2[M+H]+550.0778,found 550.0847。
(Z)-3-溴-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-4)
橙黄色固体，产率60.1％，Mp：288-290℃。1H NMR(400MHz,DMSO-d6)δ13.26(s,1H),10.29(s,1H),8.17(s,1H),8.05(d,J＝0.8Hz,1H),7.98(d,J＝6.9Hz,1H),7.80(d,J＝7.9Hz,1H),7.62(s,2H),7.57–7.49(m,2H),7.44(d,J＝7.2Hz,1H),7.27(d,J＝6.6Hz,1H),7.03(d,J＝7.4Hz,1H),6.09(s,1H),5.11(s,2H),2.36(s,3H),2.34(s,3H).13C NMR(100MHz,DMSO-d6)δ168.07(s),164.12(s),138.74(s),137.62(s),137.50(s),135.19(s),134.69(s),133.79(s),133.58(s),131.67(s),131.67(s),131.16(s),130.60(s),130.47(s),129.69(s),127.93(s),127.21(s),127.09(s),125.41(s),124.31(s),122.18(s),119.76(s),113.59(s),112.25(s),111.10(s),109.03(s),42.26(s),14.05(s),11.82(s).HRMS(ESI):calcd for C29H22BrCl2N3O2[M+H]+594.0272,found 594.0324。
(Z)-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-5)
橙黄色固体，产率61.3％，Mp：288-289℃。1H NMR(400MHz,DMSO-d6)δ13.26(s,1H),10.17(s,1H),8.08(s,1H),7.99(d,J＝7.3Hz,2H),7.64–7.52(m,6H),7.45(d,J＝8.2Hz,1H),7.28(d,J＝7.9Hz,1H),7.02(d,J＝8.2Hz,1H),6.08(s,1H),5.11(s,2H),2.36(s,3H),2.34(s,3H).13C NMR(100MHz,DMSO-d6)δ168.09(s),165.67(s),138.76(s),137.50(s),135.37(s),135.04(s),134.14(s),133.46(s),131.93(s),131.67(s),131.42(s),130.47(s),129.70(s),128.85(s),127.99(s),127.93(s),127.08(s),125.37(s),124.24(s),119.75(s),113.55(s),112.23(s),111.23(s),109.00(s),99.99(s),42.27(s),14.05(s),11.81(s).HRMS(ESI):calcd for C29H23Cl2N3O3[M+H]+516.1167,found 516.1232。
(Z)-4-甲氧基-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-6)
棕黄色固体，产率59.1％，Mp：294-296℃。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),10.02(s,1H),8.05(s,1H),7.98(d,J＝7.2Hz,2H),7.60(d,J＝6.4Hz,2H),7.55(s,1H),7.42(d,J＝7.1Hz,1H),7.27(d,J＝7.0Hz,1H),7.06(d,J＝7.9Hz,2H),7.01(d,J＝7.4Hz,1H),6.07(s,1H),5.10(s,2H),3.84(s,3H),2.36(s,3H),2.33(s,3H).13C NMR(100MHz,DMSO-d6)δ168.07(s),165.08(s),162.27(s),138.77(s),137.46(s),134.89(s),134.31(s),133.42(s),131.66(s),131.43(s),130.46(s),129.90(s),129.69(s),127.93(s),127.39(s),127.07(s),125.32(s),124.19(s),119.76(s),114.07(s),113.53(s),112.26(s),111.28(s),108.97(s),55.89(s),42.26(s),14.05(s),11.81(s).HRMS(ESI):calcdfor C30H25Cl2N3O3[M+H]+546.1273,found 546.1321。
(Z)-3-甲基-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-7)
橙黄色固体，产率49.4％，Mp：264-266℃。1H NMR(400MHz,DMSO-d6)δ13.26(s,1H),10.13(s,1H),8.07(s,1H),7.82–7.75(m,2H),7.61(d,J＝8.1Hz,2H),7.55(s,1H),7.43(dd,J＝15.8,7.5Hz,3H),7.28(d,J＝8.1Hz,1H),7.02(d,J＝8.4Hz,1H),6.08(s,1H),5.11(s,2H),2.41(s,3H),2.36(s,3H),2.34(s,3H).13C NMR(100MHz,DMSO-d6)δ168.07(s),165.78(s),138.76(s),138.14(s),137.51(s),135.36(s),134.99(s),134.18(s),133.46(s),132.50(s),131.67(s),131.42(s),130.47(s),129.69(s),128.76(s),128.49(s),127.93(s),127.07(s),125.35(s),125.16(s),124.20(s),119.67(s),113.55(s),112.14(s),111.22(s),108.99(s),42.25(s),21.46(s),14.05(s),11.81(s).HRMS(ESI):calcdfor C30H25Cl2N3O2[M+H]+530.1324,found 530.1374。
(Z)-4-甲基-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-8)
橙黄色固体，产率54.5％，Mp：296-298℃。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),10.09(s,1H),8.07(s,1H),7.90(d,J＝8.0Hz,2H),7.61(d,J＝7.8Hz,2H),7.56(s,1H),7.44(d,J＝9.4Hz,1H),7.34(d,J＝7.9Hz,2H),7.28(d,J＝7.9Hz,1H),7.02(d,J＝8.3Hz,1H),6.08(s,1H),5.11(s,2H),2.40(s,3H),2.36(s,3H),2.34(s,3H).13C NMR(100MHz,DMSO-d6)δ168.07(s),165.50(s),148.05(s),141.90(s),138.76(s),137.48(s),134.96(s),133.45(s),132.48(s),131.66(s),131.42(s),130.47(s),129.69(s),129.38(s),128.02(s),127.93(s),127.07(s),125.34(s),124.21(s),119.76(s),113.54(s),112.25(s),111.25(s),108.98(s),42.25(s),21.47(s),14.05(s),11.81(s).HRMS(ESI):calcdfor C30H25Cl2N3O2[M+H]+530.1324,found 530.1381。
(Z)-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)吡啶甲酰胺(III-9)
棕黄色固体，产率44.8％，Mp：268-270℃。1H NMR(400MHz,DMSO-d6)δ13.26(s,1H),10.39(s,1H),9.14(s,1H),8.77(d,J＝3.5Hz,1H),8.32(d,J＝7.2Hz,1H),8.08(s,1H),7.65–7.55(m,4H),7.44(d,J＝8.0Hz,1H),7.27(d,J＝8.2Hz,1H),7.04(d,J＝8.3Hz,1H),6.08(s,1H),5.11(s,2H),2.36(s,3H),2.33(s,3H).13C NMR(100MHz,DMSO-d6)δ168.07(s),164.16(s),152.52(s),149.08(s),138.73(s),137.61(s),135.78(s),135.23(s),133.75(s),133.58(s),131.67(s),131.42(s),130.94(s),130.48(s),129.69(s),127.93(s),127.10(s),125.44(s),124.31(s),123.99(s),119.70(s),113.58(s),112.19(s),111.08(s),109.06(s),42.26(s),14.05(s),11.81(s).HRMS(ESI):calcd for C28H22Cl2N4O2[M+H]+517.1120,found517.1182。
(Z)-2-氯-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)乙酰胺(III-10)
棕黄色固体，产率45.1％，Mp：248-250℃。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),10.20(s,1H),7.91(s,1H),7.60(d,J＝7.8Hz,2H),7.53(s,1H),7.29–7.24(m,2H),6.99(d,J＝8.3Hz,1H),6.08(s,1H),5.09(s,2H),4.25(s,2H),2.36(s,3H),2.33(s,3H).13C NMR(100MHz,DMSO-d6)δ168.01(s),164.84(s),138.71(s),137.70(s),135.05(s),133.71(s),133.46(s),131.66(s),131.42(s),130.49(s),129.69(s),127.93(s),127.08(s),125.56(s),124.43(s),118.53(s),113.62(s),110.98(s),109.17(s),43.96(s),42.22(s),14.05(s),11.80(s).HRMS(ESI):calcd for C24H20Cl3N3O2[M+H]+488.0621,found 488.0700。
(Z)-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)环丙甲酰胺(III-11)
棕黄色固体，产率42.1％，Mp：264-266℃。1H NMR(400MHz,DMSO-d6)δ13.25(s,1H),10.08(s,1H),7.94(s,1H),7.63–7.57(m,2H),7.48(s,1H),7.29–7.22(m,2H),6.95(d,J＝8.4Hz,1H),6.07(s,1H),5.08(s,2H),2.35(s,3H),2.32(s,3H),1.79–1.73(m,1H),0.78(t,J＝6.0Hz,4H).13C NMR(100MHz,DMSO-d6)δ171.77(s),168.00(s),138.77(s),137.44(s),134.59(s),134.40(s),133.40(s),131.64(s),131.41(s),130.45(s),129.68(s),127.93(s),127.01(s),125.37(s),124.11(s),118.09(s),113.52(s),111.26(s),110.51(s),109.09(s),42.20(s),14.84(s),14.04(s),11.80(s),7.38(s).HRMS(ESI):calcd forC26H23Cl2N3O2[M+H]+480.1167,found 480.1219。
(Z)-3-氟-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-12)
棕黄色固体，产率37.2％，Mp：254-256℃。1H NMR(400MHz,DMSO-d6)δ13.28(s,1H),10.25(s,1H),8.06(s,1H),7.82(dd,J＝21.2,7.7Hz,2H),7.65–7.54(m,2H),7.42(dd,J＝14.3,12.1Hz,4H),7.16(d,J＝4.3Hz,1H),7.04(d,J＝7.5Hz,1H),6.08(s,1H),5.09(s,2H),2.36(s,3H),2.33(s,3H).13C NMR(100MHz,DMSO-d6)δ168.04(s),164.22(d,J＝2.6Hz),162.44(d,J＝244.5Hz),150.29(dd,J＝20.2,12.8Hz),148.35(dd,J＝85.0,16.6Hz),137.62(s),137.49(s),135.23(s),133.59(d,J＝31.2Hz),131.06(d,J＝7.9Hz),127.08(s),125.40(d,J＝1.2Hz),124.46(dd,J＝5.3,2.3Hz),124.22(s),119.77(s),118.85(d,J＝20.9Hz),118.35(s),118.15(d,J＝7.0Hz),117.00(d,J＝2.9Hz),116.83(d,J＝4.7Hz),114.92(s),114.69(s),113.53(s),112.27(s),111.22(s),109.04(s),42.36(s),14.05(s),11.82(s).HRMS(ESI):calcd for C29H22F3N3O2[M+H]+502.1664,found502.1722。
(Z)-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-13)
棕黄色固体，产率56.9％，Mp：248-249℃。1H NMR(400MHz,DMSO-d6)δ13.28(s,1H),10.18(s,1H),8.08(s,1H),7.98(d,J＝7.2Hz,2H),7.61–7.52(m,4H),7.47–7.37(m,3H),7.16(d,J＝6.6Hz,1H),7.03(d,J＝8.4Hz,1H),6.08(s,1H),5.09(s,2H),2.36(s,3H),2.33(s,3H).13C NMR(100MHz,DMSO-d6)δ168.04(s),165.64(s),148.58(d,J＝13.0Hz),147.95(d,J＝13.8Hz),137.41(s),135.34(s),135.08(s),134.07(s),133.36(s),131.94(s),128.86(s),128.00(s),127.06(s),125.35(s),124.47(dd,J＝6.7,3.1Hz),124.17(s),121.07(s),119.74(s),118.27(d,J＝17.2Hz),116.94(d,J＝17.4Hz),113.51(s),112.24(s),111.31(s),109.02(s),42.34(s),14.06(s),11.82(s).HRMS(ESI):calcd forC29H23F2N3O2[M+H]+484.1758,found 484.1805。
(Z)-3-甲基-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺(III-14)
棕黄色固体，产率53.7％，Mp：258-260℃。1H NMR(400MHz,DMSO-d6)δ13.28(s,1H),10.13(s,1H),8.06(s,1H),7.82–7.75(m,2H),7.55(s,1H),7.46–7.37(m,5H),7.19–7.14(m,1H),7.03(d,J＝8.4Hz,1H),6.08(s,1H),5.09(s,2H),2.41(s,3H),2.36(s,3H),2.33(s,3H).13C NMR(100MHz,DMSO-d6)δ168.04(s),165.73(s),148.57(dd,J＝12.9,2.8Hz),147.92(dd,J＝9.1,5.6Hz),138.12(s),137.39(s),135.35(s),135.29(s),135.18(dd,J＝8.9,3.9Hz),135.03(s),134.14(s),133.33(s),132.49(s),128.75(s),128.50(s),127.06(s),125.33(s),125.17(s),124.47(dd,J＝6.2,3.5Hz),124.13(s),119.66(s),118.27(d,J＝17.1Hz),116.94(d,J＝17.5Hz),113.50(s),112.15(s),111.33(s),109.00(s),42.34(s),21.46(s),14.05(s),11.81(s).HRMS(ESI):calcd for C30H25F2N3O2[M+H]+498.1915,found 498.1964。
(Z)-2-氯-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)乙酰胺(III-15)
棕黄色固体，产率40.6％，Mp：236-237℃。1H NMR(400MHz,DMSO-d6)δ13.27(s,1H),10.19(s,1H),7.90(s,1H),7.52(s,1H),7.41(d,J＝6.2Hz,2H),7.26(d,J＝6.7Hz,1H),7.14(s,1H),7.00(d,J＝6.8Hz,1H),6.07(s,1H),5.06(s,2H),4.24(s,2H),2.35(s,3H),2.33(s,3H).13C NMR(100MHz,DMSO-d6)δ168.00(s),164.82(s),150.47(dd,J＝63.4,47.4Hz),149.00(dd,J＝55.8,11.9Hz),137.58(d,J＝1.1Hz),135.26(dd,J＝5.5,1.5Hz),135.11(s),133.50(d,J＝16.0Hz),127.07(s),125.55(s),124.52(s),124.46(dd,J＝5.0,2.2Hz),124.36(s),118.52(s),118.35(s),118.18(s),116.93(d,J＝17.2Hz),113.58(s),111.01(d,J＝8.8Hz),109.18(s),43.96(s),42.34(s),14.05(s),11.80(s).HRMS(ESI):calcd for C24H20ClF2N3O2[M+H]+456.1212,found 456.1273。
(Z)-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)环丙甲酰胺(III-16)
棕黄色固体，产率47.9％，Mp：260-262℃。1H NMR(400MHz,DMSO-d6)δ13.27(s,1H),10.07(s,1H),7.93(s,1H),7.47(s,1H),7.39(d,J＝8.5Hz,2H),7.24(d,J＝6.5Hz,1H),7.14(s,1H),6.95(d,J＝6.7Hz,1H),6.06(s,1H),5.05(s,2H),2.35(s,3H),2.31(s,3H),1.79(dd,J＝19.3,3.7Hz,1H),0.79(s,4H).13C NMR(100MHz,DMSO-d6)δ171.73(s),167.98(s),150.25(d,J＝170.6Hz),148.19(d,J＝65.4Hz),137.30(s),135.32(d,J＝2.5Hz),135.25(s),134.51(d,J＝9.2Hz),133.24(s),127.01(s),125.37(s),124.46(dd,J＝6.4,3.2Hz),123.99(s),118.33(s),118.12(d,J＝8.2Hz),116.91(d,J＝16.9Hz),113.46(s),111.39(s),110.49(s),109.09(s),42.31(s),14.84(s),14.03(s),11.79(s),7.36(s).HRMS(ESI):calcd for C26H23F2N3O2[M+H]+448.1758,found 448.1804。
试验例
对人外周血T淋巴白血病细胞Jurkat、肺癌细胞A549和结肠癌细胞HCT116生长抑制活性测定实验
化合物对Jurkat细胞生长抑制活性实验、对Jurkat、A549和HCT116细胞的IC50值：
采用SRB(sulforhodamine B)试验法检测化合物对肿瘤细胞系的生长抑制活性。人外周血T淋巴源性白血病细胞Jurkat、肺癌细胞A549和结肠癌细胞HCT116用含有10％FBS、2mM谷氨酰胺、100IU/mL青霉素、100μg/mL链霉素的RPMI 1640培养液供应培养。所有细胞均置于37℃含5％CO2的培养箱(Thermo Forma)中，常规传代培养。将处于对数生长期的细胞以一定数量接种于96孔板(200μl/孔)中，培养24小时使之贴壁后加药。每个化合物的单个药物浓度设1个复孔，并设相应的调零组及空白对照组。药物作用72小时后，往Jurkat或A549或HCT116细胞中加入50％TCA(三氯乙酸)(50μl/孔)，4℃下固定1小时后倒掉固定液，用蒸馏水依次洗5次，自然干燥。向每孔中加入100μL 4mg/mL的SRB，室温染色15分钟，弃之，分别用1％冰醋酸洗5次，自然干燥。最后向每孔中加入150μL 10mM的Tris缓冲溶液，摇匀，用可调波长式微孔板酶标仪(VERSAmaxTM，Molecular Device)在565nm波长下测定OD值。用以下公式计算细胞生长抑制率。
抑制率(％)＝(OD值对照孔－OD值给药孔)/OD值对照孔×100％
根据每个化合物的单个药物浓度设1个复孔计算各化合物的抑制率，数据表示为均值±SD值。
优选的目标化合物设计了9个梯度浓度，并设置了两个对照组，根据以上公式分别计算各浓度抑制率，采用LOGIT法计算半数抑制浓度IC50。实验重复进行1次，数据表示为均值±SD值，如表1、表2所示。
表1.目标化合物在10μM浓度下对Jurkat细胞的生长抑制活性
与对照药物司马沙尼(SU5416)相比，I-3、I-9、I-13、Ⅱ-2、Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12、III-9对Jurkat细胞的生长抑制活性优于阳性化合物司马沙尼(SU5416)，其中Ⅱ-2、Ⅱ-3、Ⅱ-5、Ⅱ-10、Ⅱ-11和III-9对Jurkat细胞的生长抑制活性大于50％。进一步地，我们优选了目标化合物Ⅱ-2、Ⅱ-3、Ⅱ-5、Ⅱ-10、Ⅱ-11和III-9，以化合物AA-2(1-(3,4-二氯苄基)-1H-吲哚-2,3-二酮)为对照药物，分别测定了它们对人外周血T淋巴白血病细胞Jurkat、肺癌细胞A549和结肠癌细胞HCT116的IC50值，实验结果见表2。
表2.优选的目标化合物对人外周血T淋巴白血病细胞Jurkat、肺癌细胞A549和结肠癌细胞HCT116的IC50值
注：ND：Not Detected.
Ⅱ-3、Ⅱ-5、Ⅱ-10、Ⅱ-11和III-9对Jurkat、A549或HCT116细胞呈现出低微摩尔浓度(小于8.5μM)的生长抑制活性。其中，Ⅱ-5对Jurkat和A549细胞的生长抑制活性优于阳性化合物AA-2，而Ⅱ-11对Jurkat、A549和HCT116三株细胞系的生长抑制活性均优于阳性化合物AA-2。
Claims (15)
1.一种3-取代吲哚-2-酮化合物，其特征在于，所述3-取代吲哚-2-酮化合物选自以下化合物：
(Z)-1-(3-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(4-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(3-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(4-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(3-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(4-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(3-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(4-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(3-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(4-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(3,4-二甲氧基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮；
(Z)-1-(3-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(4-氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(3-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(4-氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(3-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(4-溴苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(3-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(4-氰基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(3-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(4-三氟甲基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮；
(Z)-1-(3,4-二甲氧基苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-5-氨基-2-吲哚酮。
2.一种3-取代吲哚-2-酮化合物，其特征在于，所述3-取代吲哚-2-酮化合物选自以下化合物：
(Z)-3-氟-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-4-氟-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-3-氯-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-3-溴-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-4-甲氧基-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-3-甲基-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-4-甲基-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)吡啶甲酰胺；
(Z)-2-氯-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)乙酰胺；
(Z)-N-(1-(3,4-二氯苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)环丙甲酰胺；
(Z)-3-氟-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-3-甲基-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)苯甲酰胺；
(Z)-2-氯-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)乙酰胺；
或，(Z)-N-(1-(3,4-二氟苄基)-3-((3,5-二甲基-1H-吡咯-2-基)亚甲基)-2-吲哚酮-5-基)环丙甲酰胺。
3.如权利要求1或2所述3-取代吲哚-2-酮化合物的制备方法，其特征在于，合成路线如下所示：
其中，R1、R2与权利要求1或2中各化合物的取代基相同。
4.根据权利要求3所述3-取代吲哚-2-酮化合物的制备方法，其特征在于，所述3-取代吲哚-2-酮化合物的制备方法，包括步骤：
以2-吲哚酮即化合物1为起始原料，与3,5-二甲基-1H-吡咯-2-甲醛经羟醛缩合反应生成中间体2；中间体2在K2CO3存在的条件下与取代苄氯或取代苄溴经亲核取代反应得式(I)化合物；
或者，以2-吲哚酮即化合物1为起始原料，经硝化反应生成中间体3；中间体3与3,5-二甲基-1H-吡咯-2-甲醛经羟醛缩合反应生成中间体4；中间体4在K2CO3存在的条件下与取代苄氯或取代苄溴经亲核取代反应生成中间体5；中间体5经铁粉还原得式(II)化合物；
或者，所得式(II)化合物与相应的羧酸经酰胺缩合反应，或在K2CO3存在的条件下与相应的酰氯经酰氯化反应得式(III)化合物。
5.一种药物组合物，其包含如权利要求1所述的3-取代吲哚-2-酮化合物或其药学上可接受的盐。
6.一种药物组合物，其包含如权利要求2所述的3-取代吲哚-2-酮化合物或其药学上可接受的盐。
7.一种药物制剂，其包含如权利要求1所述的3-取代吲哚-2-酮化合物或其药学上可接受的盐和至少一种药学上可接受的辅料或载体。
8.一种药物制剂，其包含如权利要求2所述的3-取代吲哚-2-酮化合物或其药学上可接受的盐和至少一种药学上可接受的辅料或载体。
9.权利要求1所述3-取代吲哚-2-酮化合物或权利要求5所述的药物组合物或权利要求7所述的药物制剂在制备人外周血T淋巴源性白血病细胞、肺癌细胞和/或结肠癌细胞生长抑制剂中的应用。
10.权利要求2所述3-取代吲哚-2-酮化合物或权利要求6所述的药物组合物或权利要求8所述的药物制剂在制备人外周血T淋巴源性白血病细胞生长抑制剂中的应用。
11.根据权利要求9或10所述的应用，其特征在于，所述人外周血T淋巴源性白血病细胞为Jurkat，所述肺癌细胞为A549，结肠癌细胞为HCT116。
12.权利要求1所述3-取代吲哚-2-酮化合物或权利要求5所述的药物组合物或权利要求7所述的药物制剂在制备抗肿瘤药物中的应用。
13.权利要求2所述3-取代吲哚-2-酮化合物或权利要求6所述的药物组合物或权利要求8所述的药物制剂在制备抗肿瘤药物中的应用。
14.根据权利要求12所述的应用，其特征在于，所述肿瘤为白血病、肺癌或结肠癌。
15.根据权利要求13所述的应用，其特征在于，所述肿瘤为白血病。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211150957.5A CN115403566B (zh) | 2022-09-21 | 2022-09-21 | 3-取代吲哚-2-酮化合物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211150957.5A CN115403566B (zh) | 2022-09-21 | 2022-09-21 | 3-取代吲哚-2-酮化合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115403566A CN115403566A (zh) | 2022-11-29 |
| CN115403566B true CN115403566B (zh) | 2024-01-30 |
Family
ID=84166275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211150957.5A Active CN115403566B (zh) | 2022-09-21 | 2022-09-21 | 3-取代吲哚-2-酮化合物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115403566B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1046525A (zh) * | 1989-04-18 | 1990-10-31 | 美国辉瑞有限公司 | 3-取代-2-羟吲哚衍生物 |
| WO1992007830A2 (en) * | 1990-10-29 | 1992-05-14 | Pfizer Inc. | Oxindole peptide antagonists |
| CN1365972A (zh) * | 2001-01-19 | 2002-08-28 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| CN104130176A (zh) * | 2014-06-13 | 2014-11-05 | 天津科技大学 | 一种1,5-二取代吲哚酮类衍生物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020028936A1 (en) * | 1999-04-12 | 2002-03-07 | Gerhard Sperl | 1,3-disubstituted indolin-2-ones for neoplasia |
| WO2005058309A1 (en) * | 2003-12-16 | 2005-06-30 | Leo Pharma A/S | Novel therapeutic use of indolinone derivatives |
-
2022
- 2022-09-21 CN CN202211150957.5A patent/CN115403566B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1046525A (zh) * | 1989-04-18 | 1990-10-31 | 美国辉瑞有限公司 | 3-取代-2-羟吲哚衍生物 |
| WO1992007830A2 (en) * | 1990-10-29 | 1992-05-14 | Pfizer Inc. | Oxindole peptide antagonists |
| CN1365972A (zh) * | 2001-01-19 | 2002-08-28 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| CN104130176A (zh) * | 2014-06-13 | 2014-11-05 | 天津科技大学 | 一种1,5-二取代吲哚酮类衍生物及其应用 |
Non-Patent Citations (5)
| Title |
|---|
| Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents;Jacqueline L. Whatmore 等;Angiogenesis;第5卷;第45-51页 * |
| Facile synthesis of various nitro-substituted derivatives of Semaxinib (SU5416);Torsten Kniess 等;Synthetic Communications;第38卷(第17期);第3017-3022页 * |
| Lesley Maskell 等.Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles.Bioorganic & Medicinal Chemistry Letters.2007,第17卷第1575-1578页. * |
| Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles;Lesley Maskell 等;Bioorganic & Medicinal Chemistry Letters;第17卷;第1575-1578页 * |
| Synthesis of potential prodrug systems for reductive activation. Prodrugs for anti-angiogenic isoflavones and VEGF receptor tyrosine kinase inhibitory oxindoles;Emilie A. Blanche 等;Tetrahedron;第65卷;第4894-4903页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115403566A (zh) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100358893C (zh) | 一些新的咪唑并吡啶及其用途 | |
| CA2830742C (en) | Substituted oxanes as opioid receptor ligands and methods of using and making same | |
| CN110256421A (zh) | Kras-g12c抑制剂 | |
| JP5302884B2 (ja) | Ｖｒ１のベンゾイミダゾール系モジュレーター | |
| ES2387780T3 (es) | Preparación de azabencimidazoles 1,6-disustituidos como inhibidores de quinasas | |
| CN116554168A (zh) | Cxcr4抑制剂及其用途 | |
| JP2000511167A (ja) | 酸性基を有するフエニル誘導体、その製造方法及びそれをクロライドチャンネル遮断剤として使用する方法 | |
| WO2017114509A1 (zh) | 醛基类化合物及其制法和用途 | |
| JP2000502724A (ja) | インダゾール誘導体、およびホスホジエステラーゼ（ｐｄｅ）タイプ▲ｉｖ▼と腫瘍壊死因子（ｔｎｆ）産生の阻害剤としてのインダゾール誘導体の使用 | |
| CN111662296B (zh) | 一种含吡唑并嘧啶的异羟肟酸衍生物及其制备方法和应用 | |
| PT2125776T (pt) | Compostos espiro substituídos como inibidores da angiogénese | |
| KR20070025900A (ko) | 혈관신생 억제제로서의 6환 아미노-아미드 유도체 | |
| AU2018257203B2 (en) | Novel tetrahydronaphthyl urea derivatives | |
| JP2006512293A (ja) | ＩｇＥを調節し、細胞増殖を阻害するためのフェニル−インドール化合物 | |
| CN105473573A (zh) | 用作激酶抑制剂的咔唑甲酰胺化合物 | |
| JP2021523168A (ja) | がん幹細胞を標的化するがん治療 | |
| EP2861562A1 (en) | Pyrazole derivatives as inhibitors of stat3 | |
| WO1992012144A1 (fr) | Compose cyclique condense de benzoxa, son procede de production, et composition pharmaceutique le contenant | |
| WO2021000770A1 (zh) | 可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用 | |
| CN106795152A (zh) | 蛋白激酶抑制剂 | |
| WO2013170757A1 (zh) | 4-氨基喹唑啉异羟肟酸类化合物及作为抗肿瘤药物应用 | |
| CN115403566B (zh) | 3-取代吲哚-2-酮化合物及其制备方法和应用 | |
| WO2017190708A1 (zh) | 吡唑‐三嗪类衍生物、其制备方法、药物组合物和用途 | |
| TW201922690A (zh) | 環－amp反應元素結合蛋白的抑制劑 | |
| WO2020253802A1 (zh) | 二芳基酰胺类化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |